FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT)

Historical Holders from Q1 2014 to Q3 2025

Symbol
FBT
Type / Class
Equity / NY ARCA BIOTECH
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
3,031,630
Holdings value
$543,973,105
% of all portfolios
0.002%
Number of holders
249
Number of buys
97
Number of sells
-105
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 3,031,630 $543,973,105 -$12,931,716 $179.29 249
2025 Q2 3,155,408 $509,245,856 -$41,077,763 $161.33 247
2025 Q1 3,418,328 $576,824,224 +$1,866,805 $170.12 266
2024 Q4 3,418,857 $568,580,158 +$41,645,148 $166.21 253
2024 Q3 3,143,605 $540,228,542 -$50,274,497 $171.93 252
2024 Q2 3,468,418 $534,289,452 +$6,575,921 $153.99 247
2024 Q1 3,399,038 $522,621,545 -$94,532,990 $153.77 240
2023 Q4 4,017,594 $634,837,157 -$30,986,867 $158.06 254
2023 Q3 4,190,296 $613,262,596 -$62,820,801 $146.35 239
2023 Q2 4,617,487 $707,129,055 -$19,966,454 $153.14 247
2023 Q1 4,700,385 $728,635,260 -$18,428,171 $155.03 241
2022 Q4 4,877,768 $751,529,554 +$55,433,739 $154.13 239
2022 Q3 4,496,690 $593,813,874 +$22,209,350 $131.98 212
2022 Q2 4,332,609 $587,753,929 -$18,206,139 $135.56 218
2022 Q1 4,448,675 $663,407,924 -$82,106,064 $149.14 212
2021 Q4 4,955,742 $802,113,791 -$46,741,875 $161.96 239
2021 Q3 5,178,909 $859,978,174 -$14,178,042 $166.06 230
2021 Q2 5,220,166 $900,985,426 -$80,585,265 $172.62 227
2021 Q1 5,725,862 $919,195,735 -$21,822,779 $160.5 232
2020 Q4 5,809,688 $976,622,166 -$78,183,499 $167.99 232
2020 Q3 6,096,208 $959,021,765 -$32,144,151 $157.26 210
2020 Q2 6,226,658 $1,045,067,619 +$191,623,157 $167.77 222
2020 Q1 5,157,697 $676,659,157 -$47,084,204 $131.12 193
2019 Q4 5,487,562 $816,287,431 -$74,667,369 $148.72 207
2019 Q3 5,992,894 $742,538,774 -$882,858,217 $123.76 184
2019 Q2 12,569,930 $1,770,181,894 +$35,822,419 $140.84 217
2019 Q1 12,360,195 $1,864,503,721 +$128,595,965 $150.85 224
2018 Q4 11,657,169 $1,449,690,480 -$403,797,433 $124.2 190
2018 Q3 14,181,041 $2,246,741,087 +$1,432,250,063 $158.49 187
2018 Q2 5,133,431 $718,724,343 +$63,854,991 $140.01 154
2018 Q1 4,683,224 $622,474,212 +$91,611,191 $132.9 152
2017 Q4 3,984,755 $496,314,617 +$44,748,999 $124.57 126
2017 Q3 3,605,567 $446,754,001 +$14,480,513 $123.93 115
2017 Q2 3,492,182 $398,275,105 +$56,018,406 $114.04 112
2017 Q1 3,018,492 $316,695,674 -$4,736,324 $105.3 113
2016 Q4 3,095,489 $281,588,359 +$13,238,858 $90.87 107
2016 Q3 2,930,364 $291,496,084 -$4,711,885 $99.71 110
2016 Q2 3,076,251 $274,668,626 -$39,232,497 $89.43 105
2016 Q1 3,349,153 $294,129,961 -$1,892,206,413 $87.56 102
2015 Q4 21,779,226 $2,459,415,016 +$164,656,445 $113.02 127
2015 Q3 20,090,644 $2,036,625,833 +$162,029,493 $101.32 126
2015 Q2 18,456,703 $2,288,765,259 +$285,028,551 $124.02 123
2015 Q1 16,117,838 $1,905,196,132 +$443,224,811 $118.23 119
2014 Q4 12,339,312 $1,258,885,285 +$245,972,458 $102.02 109
2014 Q3 9,633,125 $883,813,866 +$85,577,040 $91.78 95
2014 Q2 8,789,399 $715,910,314 +$32,118,674 $82.33 92
2014 Q1 8,321,792 $638,198,251 +$51,685,578 $76.69 81